Back to search results

A Study of Elritercept for Anemia in Myelodysplastic Syndromes

This study is comparing two medications, Elritercept and Epoetin Alfa, to treat anemia (low red blood cells) in adults with certain types of Myelodysplastic Syndromes (MDS). MDS is a group of disorders where the bone marrow doesn't make enough healthy blood cells. Participants in this study need regular blood transfusions. The main goal is to see if Elritercept can reduce your need for red blood cell transfusions and if it's safe. We also want to learn if Elritercept can improve tiredness and your quality of life compared to Epoetin Alfa. The study will also look at how your body's immune system reacts to Elritercept and any medical problems that might occur.

Study design
This study plans to enroll 300 participants. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured over a 24-week period, with each cycle lasting 28 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07422480

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Recruiting
PHASE3Ages 18+InterventionalTreatment
Takeda
~300 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:ElriterceptEpoetin Alfa

At a glance

Recruiting sites
37 of 156 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From Baseline
Measured over From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)

Conditions

Myelodysplastic Syndrome
Anemia

Explore related trials

Myelodysplastic Syndrome

Where it's being run

156 sites across 105 states
Texas6
Italy6
Spain5
Taiwan5
Victoria4
Ireland4
South Korea4
California3

Study leadership

  • Study Director · STUDY_DIRECTOR · Takeda

Who to contact

Takeda Contact
[email protected]
+1-877-825-3327
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From BaselineFrom Cycle 1 Day 1 through Week 24 (each cycle is 28 days)

    RBC-TI is defined as no red blood cell (RBC) transfusions administered for the specified time period during study treatment.